Drugs / LY3415244
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03752177 | Nov 2018 → Oct 2019 | neoplasm | Eli Lilly and Company | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3415244 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03752177 ↗ |
| Route | Intravenous | “Administered IV” NCT03752177 ↗ |